Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

Thompson, 2010, Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel, JAMA, 304, 321, 10.1001/jama.2010.1004

Gazzard, 2008, British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008, HIV Med, 9, 563, 10.1111/j.1468-1293.2008.00636.x

Chesney, 2000, Factors affecting adherence to antiretroviral therapy, Clin Infect Dis, 30, S171, 10.1086/313849

Willig, 2008, Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy, AIDS, 22, 1951, 10.1097/QAD.0b013e32830efd79

DeJesus, 2006, Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients, J Acquir Immune Defic Syndr, 43, 1, 10.1097/01.qai.0000233308.82860.2f

Gallant, 2004, Protease-inhibitor boosting in the treatment-experienced patient, AIDS Rev, 6, 226

Mathias, 2009, Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure., Clin Pharmacol Ther, 85, 64, 10.1038/clpt.2008.168

Mathias, 2010, Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity, Clin Pharmacol Ther, 87, 322, 10.1038/clpt.2009.228

Zolopa, 2010, Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial, J Infect Dis, 201, 814, 10.1086/650698

Shafran, 2005, The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations, HIV Med, 6, 421, 10.1111/j.1468-1293.2005.00328.x

German, 2010, Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV, J Acquir Immune Defic Syndr, 55, 323, 10.1097/QAI.0b013e3181eb376b

Markowitz, 2007, Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study, J Acquir Immune Defic Syndr, 46, 125, 10.1097/QAI.0b013e318157131c

Lennox, 2009, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, Lancet, 374, 796, 10.1016/S0140-6736(09)60918-1

Rihs, 2006, Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study, HIV Med, 7, 544, 10.1111/j.1468-1293.2006.00419.x

Cespedes, 2006, Neuropsychiatric complications of antiretroviral therapy, Drug Saf, 29, 865, 10.2165/00002018-200629100-00004

Clifford, 2005, Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals, Ann Intern Med, 143, 714, 10.7326/0003-4819-143-10-200511150-00008

Pozniak, 2010, Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial, AIDS, 24, 55, 10.1097/QAD.0b013e32833032ed

Markowitz, 2009, Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection, J Acquir Immune Defic Syndr, 52, 350, 10.1097/QAI.0b013e3181b064b0

Fumaz, 2005, Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence, J Acquir Immune Defic Syndr, 38, 560, 10.1097/01.qai.0000147523.41993.47

Maggiolo, 2009, Efavirenz: a decade of clinical experience in the treatment of HIV, J Antimicrob Chemother, 64, 910, 10.1093/jac/dkp334

Sierra-Madero, 2010, Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study, HIV Clin Trials, 11, 125, 10.1310/hct1103-125